<DOC>
	<DOCNO>NCT01474499</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety docusate sodium sorbitol rectal solution produce Ferring Pharmaceutical ( China ) Ltd. treat Chinese patient constipation .</brief_summary>
	<brief_title>A Trial Docusate Sodium Sorbitol Rectal Solution Patients With Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bismuth subsalicylate</mesh_term>
	<mesh_term>Sorbitol</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>Have sign inform consent form verbally tell detail trial treatment procedure Is citizen People 's Republic China Males females age 18 65 year inclusive A history constipation symptom least 6 month , occurrence two symptom 3 month screen : 1 . More 1/4 stool classifiable Type I Type II Bristol Stool Scale ; 2 . Sensation incomplete evacuation least 1/4 time ; 3 . Straining defecation least 1/4 time ; 4 . Sensation anorectal blockage obstruction defecation least 1/4 time ; 5 . Manual manoeuvre need often facilitate defecation ( e.g . digital evacuation ) least 1/4 time ; 6 . Fewer 3 bowel movement per week No bowel movement within two day prior randomisation Patients suspect colorectal cancer ; Patients show sign bleed digestive tract inflammatory bowel disease ; Patients experience abdominal discomfort intestinal blockage cause yet determine ; Patients allergic docusate sorbitol ; Patients allergic glycerine ; Those pregnant , breastfeeding , intention become pregnant , fertile woman effective birth controlï¼ˆi.e . IUD ( intrauterine device ) , oral contraceptive obstructive measure ; Severe liver damage ( ALT ( alanine aminotransferase ) , AST ( aspartate transaminase ) , TBIL ( serum total bilirubin ) 2 time upper limit normal ) Kidney function impairment ( Cr ( creatinine clearance rate ) , BUN ( blood urea nitrogen ) 1.5 time upper limit normal ) Patients participate clinical trial last 3 month ; Diabetics currently undergo insulin treatment ; Patients unable suspend use treatment affect kinetics digestive system 5 day prior randomisation . Such treatment include prokinetic drug , erythromycin analogue , laxative , etc ; Other patient factor ( ) ( e.g . medical history , concurrent illness ( e ) , laboratory test result ( ) , etc . ) Screening opinion investigator ( ) would put trial patient excessive risk ; Patients unable act legal capacity , unable meet perform study requirement , know suspect unable comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>